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Background: The present study aimed to evaluate the added value of contrast-enhanced computed tomography
(ceCT) in comparison to standard, non-enhanced CT in the context of a combined positron emission tomography
(PET)/CT examination by means of a tumor-, site-, and clinical question-based approach.
Methods: Analysis was performed in 202 patients undergoing PET/CT consisting of a multiphase CT protocol
followed by a whole-body PET. The Cochran Q test was performed, followed by a multiple comparisons correction
(McNemar test and Bonferroni adjustment), to compare standard and contrast-enhanced PET (cePET/CT). Histopathology
or clinical-radiologic follow-up greater than 1 year was used as a reference.
Results: cePET/CT showed significantly different results with respect to standard PET/CT in head and neck and
gastrointestinal cancer (P = 0.02 and 0.0002, respectively), in the evaluation of lesions located in the abdomen (P= 0.009),
and in the context of disease restaging (P = 0.003). In all these clinical scenarios, adding ceCT resulted in a distinct benefit,
by yielding a higher percentage of change in patient management.
Conclusion: These data strongly underline the importance of strictly selecting patients for the combined exam. In
particular, patient selection should not be driven solely by mere tumor classification, but should also account for the clinical
question and the anatomical location of the neoplastic disease, which can significantly impact patient management.
Keywords: PET/CT, Contrast-enhanced PET/CT, 18 [F] fluorodeoxyglucose, Head and neck cancer, Gastrointestinal cancerBackground
Since the early 1990s, functional imaging with positron
emission tomography (PET) has been the fastest growing
diagnostic modality in oncology [1,2]. In particular, PET
with [18 F] fluorodeoxyglucose (FDG), which exploits the in-
creased glucose uptake and metabolism by the rapidly pro-
liferating cancer cells, has opened a new field in clinical
imaging and is widely used for staging, restaging, therapeutic* Correspondence: silviadaniela.morbelli@hsanmartino.it
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unless otherwise stated.response monitoring, and prognostic evaluation in patients
affected by several types of cancers. However, PET imaging
alone is unable to provide precise anatomical localization.
Moreover, its utility is often limited by the contextual pres-
ence of augmented, non-disease-related glucose uptake in
several anatomical districts. These findings can range from
the physiologically increased uptake in organs, such as the
heart, liver, voluntary muscles, and brain, to paraphysiologi-
cal scenarios, such as FDG hyperaccumulation in skeletal re-
pair sites, in the active ovarian follicle, and within the active
bone marrow [3]. Inflammation is per se a common cause
of increased glucose use [3,4].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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(n = 202) (n = 73)
Age (years) 61.9 ± 14.9 54.2 ± 17.3
Gender (M/F) 120/82 43/30
Tumor typea,b
Lung cancer 38 30




Breast cancer 21 4
Lymphoma 36 9
Melanoma 19 2









Response to radiotherapy 18 6
Post-surgery evaluation 11 0
Surveillance 40 22
Values are mean ± standard deviation.
aTwo patients were not affected by any oncologic disease after
histologic confirmation.
bTumor type and clinical questions correspond to the groups submitted to the
tumor-based and question-based analyses.
cIncluding esophageal, gastric, and colorectal cancer.
dGynecologic malignancy (n = 8), testicular cancer (n = 2), sarcoma (n = 3),
low-differentiated neuroendocrine carcinoma (n = 4), thymoma (n = 1).
eSuspected relapse or patients with potentially resectable metastatic disease.
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combined PET and computed tomography (CT) in a sin-
gle scanner has become commercially available. Its emer-
gence has had a major impact on diagnostic performance
of oncology patients [4], enabling the physician to acquire
both metabolic and anatomical imaging data in a single
diagnostic session [2].
Modern PET/CT scanners incorporate the latest CT tech-
nology, thus technically allowing the execution of multi-
phase, high-quality CT imaging. Recently, there have been
several reports of the possible superiority of contrast-
enhanced PET (cePET)/contrast-enhanced CT (ceCT)
over standard PET/CT in different clinical settings, in-
cluding disease staging, restaging, presurgical evaluation,
and treatment planning of different tumor types [5-10].
However, in the vast majority of PET/CT scans, the CT
component is performed with low current setting and
without intravenous contrast, its purpose being to allow
an attenuation-weighted reconstruction of the PET sino-
grams and obtain an anatomical correlation of radiotracer
distribution. Indeed, the adoption of a low-dose, contrast-
free CT protocol has been guided mostly by practical con-
siderations, so as to reduce radiation burden, reduce patient
discomfort, and minimize scanning time, thus increasing
the number of exams that a center can perform on daily
basis. Also, the lack of large prospective trials and the ab-
sence of clinical guidelines have prevented a systematic ap-
plication of this dual-mode imaging using an evidence-
based approach.
It has, however, to be considered that the analyses per-
formed in the vast majority of published studies are mainly
focused on a tumor-based approach [5-10] in the absence
of a more ‘translational’ evaluation of the feasibility of such
a powerful, but practically complex, imaging modality. In
fact, the potential advantages of executing the CT part of a
PET/CT scan with protocol encompassing contrast admin-
istration are related to the greater anatomical details given
by ceCT, and its improved characterization of millimetric
lesions and the delineation of known lesions with respect
to surrounding tissues (i.e. the identification of infiltrative
behavior). These latter aspects may be more strictly related
to each patient’s specific clinical history (site of disease and
clinical question) rather than to the mere classification of
tumor type. For these reasons, we hypothesized that a
more comprehensive approach would help to identify pa-
tients that are more likely to benefit from cePET/CT
imaging. This approach should account not only for
tumor histopathology, but also for the site of known/
suspected lesions and for the clinical question. Thus,
the aim of the present study was to evaluate the add-
itional diagnostic value of ceCT in comparison to
standard, non-enhanced CT in the context of a com-
bined PET/CT examination by means of a tumor-,
site-, and clinical question-based approach.Methods
Patients
Between September 2007 and June 2011, 202 patients
were referred to our institution for the execution of
multimodal PET/CT, including both non-enhanced and
contrast-enhanced diagnostic CT. Clinical indication com-
prised diagnosis of suspected oncologic disease, diagnosis
of a suspected recurrence, and staging, restaging, or post-
therapy evaluation of a known oncologic disease. All
patients accepted the use of imaging data for research
purposes by providing written informed consent that
was approved by the local regulatory bodies. Patient
characteristics are summarized in Table 1. In these pa-
tients, the indications for adding a multiphase ceCT to
the standard PET/CT exam protocol were: (1) new pa-
tients with no state-of-the-art, whole-body staging
examination available; (2) equivocal or insufficient re-
sults of previous examinations; (3) precise assessment
of tumor extent before local radiation therapy; (4)
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restaging with both ceCT and PET/CT.
Positron emission tomography/computed tomography
scanning
Patients were prepared and standard PET/CT exams
were performed according to the European guidelines
[11]. Briefly, patients fasted overnight prior to the intra-
venous administration of FDG; this was performed in a
quiet room, with the patient lying in a recumbent pos-
ition and asked not to move. Blood glucose was mea-
sured before tracer injection was administered, to ensure
blood glucose levels < 160 mg/dl. The dose of FDG var-
ied between 350 and 450 MBq, depending on the pa-
tient’s weight, and was injected through a peripheral
vein catheter. To minimize artifacts caused by the pres-
ence of radioactive urine in the excretory system, pa-
tients were asked to drink 500–1000 ml of water 1 h
prior to image acquisition and to void just before the
scan. No urinary bladder catheterization was used.
Whole-body imaging was performed using a combined
PET/CT scanner (BioGraph 16 Hi-Rez PET/CT scanner;
Siemens AG, Erlangen, Germany). The technical param-
eters of the 16-detector row, helical CT scanner included
a gantry rotation speed of 0.5 s and a table speed of
24 mm per gantry rotation. The PET component of the
combined imaging system had an axial view of 16.2 cm
(per bed position), with an interslice spacing of 3.75 mm
in one bed position. The transaxial field of view and pixel
size of the reconstructed PET images were 58.5 cm and
4.57 mm, respectively, with a matrix size of 128 × 128.
Data acquisition started 60 ± 10 minutes after intravenous
tracer administration. First, unenhanced, low-dose CT
was performed at 140 kV and 40 mA for emission-based
attenuation correction, immediately followed by a PET
scan, which was executed in three-dimensional (3D)
mode, with a 3-min acquisition per bed position. The
scan was performed starting from the orbital plane on
to the mid-thigh, except for those cases where the clin-
ical history demanded a whole-body, head-to-toes scan
(e.g. multiple myeloma or melanoma). Attenuation-
corrected PET images were reconstructed by means of
an ordered-subset expectation maximization, iterative
reconstruction algorithm (three iterations, eight sub-
sets). Finally, diagnostic ceCT was performed for the
same axial coverage. The entire ceCT data set was
automatically fused with the 3D PET images using the
integrated software interface provided by the manufac-
turer (syngo Image Fusion; Siemens AG, Erlangen,
Germany) to create contrast-enhanced anatomical im-
ages superimposed with FDG uptake. We did not ex-
perience significant fusion mismatch as the ceCT was
performed immediately after the PET emission scan,
while the patient was maintaining the same position.Contrast-enhanced computed tomography technique
The CT scan was performed immediately after comple-
tion of PET acquisition, planned with the same scout
view. In most cases, a pre-contrast diagnostic scan was
not acquired and the standard acquisition protocol con-
sisted of an arterial phase scan of the upper abdomen,
starting 35 s after the start of contrast injection, followed
by a portal phase scan, extended from the skull base to
the symphysis pubis, starting 70 s after the administra-
tion of the intravenous contrast. The scan parameters
were as follows. Arterial phase: slice thickness of 5 mm,
pitch 0.8, tube rotation speed 0.5 s, 120 kV, reference
175 mA. A dose modulation system was applied to
optimize total exposure according to the patient’s body
size; an additional set of 1-mm thick slices was recon-
structed to obtain high-resolution, multiplanar reforma-
tions. Portal phase: slice thickness 5 mm, pitch 0.8, tube
rotation speed 0.5 s, 120 kV, reference 175 mA with the
same modulation system; 2-mm thick slices at 1.5 mm in-
tervals were reconstructed for multiplanar reformations.
In selected cases, a delayed scan was performed at
equilibrium or in the urographic phase, according to the
clinical question. In the follow-up of known lesions or in
patients with lymphoproliferative disorders and with
previous negative imaging examination, only the portal
phase scan was obtained, so as to reduce the dose ad-
ministered to the patient.
Iodinated contrast medium, with a concentration of
350 mg/ml, was injected using a power injector at a flow
rate of 3 ml/s and a dose of 80–130 ml, depending on
body weight, followed by 40 ml of saline at the same
flow rate. Contrast medium administration protocols
and measures aiming to prevent contrast-related adverse
effects were performed according to the guidelines of
the European Society of Urogenital Radiology [12].
Standard, 5-mm thick images were used for rapid
evaluation by the radiologist and for reviewing by the re-
ferring physician, while thinner slices were used for mul-
tiplanar imaging of vessels, bone (ribs and spine), and
for high-resolution scanning of lung and liver lesions.
Image interpretation
Positron emission tomography, ceCT, and fused images
were reconstructed for review on a dedicated computer
workstation (syngo Image Fusion; Siemens AG, Erlangen,
Germany).
Initially, PET/low-dose CT and multiphase diagnostic
CT images were evaluated independently by two experi-
enced nuclear medicine specialists and by two experienced
CT radiologists, respectively. All readers had access to the
patient’s clinical history, but were blinded to the other mo-
dality results. Subsequently, fused, cePET/CT images were
evaluated in consensus, by the combined team of radiolo-
gists and nuclear physicians. This latter consensus report
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the additional value of diagnostic CT on PET/CT image
interpretation.
In the evaluation of FDG-PET/CT, a lesion was con-
sidered positive whenever it showed a non-physiological
increase of FDG uptake. In particular, the diagnosis of a
PET-positive lesion was also supported by a maximum
standardized uptake (SUVmax) value of at least 2.5 or by
an FDG uptake exceeding the surrounding background
tissue, the blood pool radioactivity, or the average liver
uptake. However, the differentiation between malignant
and benign lesion was not based solely on SUVmax, as
the qualitative assessment of increased FDG uptake
areas played a major role in the clinical reporting. For
instance, if a lesion showed clearly abnormal focal FDG
avidity but displayed a SUVmax lower than the 2.5
threshold (e.g. due to partial volume effect in small-sized
lesions), that lesion was deemed malignant.
On diagnostic ceCT-only images, detection of a patho-
logic lesion was performed according to published cri-
teria [13-16]. For example, lymph node (LN) assessment
in the neck, thorax, and abdomen was based on size cri-
teria (1-cm short-axis diameter threshold). However, the
presence of peripheral low attenuation, suggesting a fatty
hilum within a LN, was considered a benign sign, re-
gardless of node size. Finally, criteria such as abnormal
enhancement, central necrosis, irregular borders, and the
presence of infiltrative behavior were used to characterize
soft tissue lesions. Consensus interpretation of the PET/
ceCT exam was performed according to the following
criteria: (1) positive lesions were diagnosed when an ab-
normal area of focal FDG uptake, as observed in PET im-
ages, corresponded to an abnormal finding on CT; (2)
LNs with increased glucose uptake were deemed positive
for metastatic spread even if they were smaller than 1 cm
in short-axis diameter; (3) conversely, LNs with no detect-
able tracer uptake were deemed negative for metastatic
spread, even if they were larger than 1 cm in short-axis
diameter; (4) in all the remaining cases, the two readers
decided to emphasize either functional information from
the PET or morphological information from the ceCT on
a case-by-case basis, according to type and site of disease
and in relation to the patient’s clinical history. For ex-
ample, in cePET/CT images, small pathological lesions,
such as millimetric lung metastases, which often lack
FDG accumulation, were evaluated on the basis of the
ceCT results.
Standard of reference
The final diagnosis was obtained from the results of the
histopathologic examination, obtained following surgery
or biopsy (73 patients, 147 lesions), or clinical/radio-
logical 12-month follow-up or, again, on the basis of
tumor marker levels or on the evolutionary pattern ofknown findings at subsequent imaging (129 patients,
450 lesions). Follow-up information included physical
examination, laboratory tests, tumor markers, other in-
dependent imaging studies, such as multislice CT, mag-
netic resonance imaging, FDG-PET/CT, 18 F-NaF PET/
CT, X-ray studies, and bone scans.
The criteria used as the standard of reference were:
(1) laboratory findings, such as increasing tumor markers;
(2) combination of either negative follow-up imaging find-
ings and negative clinical findings or positive clinical find-
ings with decreasing lesion size after therapy, as determined
by subsequent imaging studies; (3) increasing lesion size or
metabolic activity in the course of follow-up; (4) subsiding
of pathological findings on follow-up PET/CT studies com-
bined with negative clinical follow-up.
Statistical analysis
Statistical analysis was carried out using the ‘R’ software
program [17] and the DiagnosisMed software package [18].
We performed patient-based and lesion-, site-, tumor-,
and question-based analyses of the cePET/CT results
compared with PET/CT. Tables 1 and 2 list the tumor
type, clinical question, and site of disease that were used
in the tumor-, question-, and site-based analyses.
A lesion was included in the analysis if at least one of
the three modalities (cePET/CT, ceCT, PET/CT) deemed
it positive or if it was considered as non-pathologic at
these three modalities but resulted positive at a subse-
quent histopathologic analysis.
Sensitivity, specificity, positive predictive value, nega-
tive predictive value (NPV), accuracy, likelihood ratios,
diagnostic odds ratio, error rate, and Youden’s index
were calculated using standard statistical formulae, and
the 95% confidence interval was determined for each
parameter. Differences among imaging modalities were
assessed with the Cochran Q test, followed by multiple
comparisons using the McNemar test with continuity
correction and Bonferroni adjustment. Probability values
inferior to 0.05 were considered as statistically signifi-
cant. The value of adding a diagnostic CT to the stand-
ard PET/CT protocol was also evaluated in terms of the
impact on patient management, following the informa-
tion derived from the cePET/CT exam only. This evalu-
ation was performed on a patient basis for each tumor
type and clinical question.
In order to better characterize the additional value of
ceCT with respect to the low-dose PET/CT study, the
management-changing findings were classified into the
following categories: (1) metabolism-related; (2) site-related;
(3) dimension-related; (4) related to local infiltration or add-
itional findings on ceCT.
Category 1 referred to the improved characterization of
a lesion that presented no increment in FDG uptake or
whose uptake did not reach the significance threshold.





(n = 597) (n = 147)
Tumor typea,b
Lung cancer 104 40
Head and neck cancer 61 32
Gastrointestinal cancerc 129 24
Breast cancer 60 6
Lymphoma 125 20
Melanoma 26 10






Response to chemotherapy 58 6
Response to radiotherapy 18 6






Skeleton-bone marrow 174 20
Lymph nodesf 198 32
Values are mean ± standard deviation.
aTwo patients were not affected by any oncologic disease after
histologic confirmation.
bTumor type, clinical questions, and disease sites correspond to the groups
submitted to the tumor-based and question-based analyses.
cIncluding esophageal, gastric, and colorectal cancer.
dGynecologic malignancy (n = 8) , testicular cancer (n = 2), sarcoma (n = 3),
low-differentiated neuroendocrine carcinoma (n = 4), thymoma (n = 1).
eSuspected relapse or patients with potentially resectable metastatic disease.
fLymph nodes were computed twice: according to their position in the body
and independently from their position.
Table 3 Patient-based performance comparisons between
PET/CT and cePET/CT
PET/CT cePET/CT
Sensitivity (%) 92.79 (86.42–96.30) 98.20 (93.67–99.50)
Specificity (%) 76.92 (67.28–84.38) 76.55 (67.02–84.76)
Positive predictive
value (%)
83.06 (75.49–88.65) 83.85 (76.56–89.18)
Negative predictive
value (%)
89.74 (81.05–94.71) 97.22 (90.43–99.23)
Positive likelihood ratio 4.02 (2.75–5.88) 4.26 (2.92–6.20)
Negative likelihood ratio 0.09 (0.05–0.18) 0.02 (0.01–0.09)
Diagnostic odds ratio 41.67 (16.96–115.67) 174.43 (41.26–1593.39)
Error rate (%) 14.36 (10.19–19.86) 11.39 (7.71–16.51)
Accuracy (%) 85.64 (80.14–89.81) 88.61 (83.49–92.29)
Youden’s index 0.6972 (0.700–0.6940) 0.7512 (0.7541–0.7483)
PET, positron emission tomography; CT, computed tomography; cePET/CT,
contrast-enhanced PET/ CT.
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interpretation of lesions due to improved localization of
abnormal FDG uptake, which also allowed a better dis-
tinction between abnormal and physiological FDG uptake.
Category 3 was applied to the cases of identification of
pathologic lesions with size falling below PET image reso-
lution. Finally, category 4 referred to the evaluation of in-
filtrative behavior or to meaningful findings that had gone
undetected at the standard PET/CT scan.
Results
Overall diagnostic accuracy and patient-based analysis
Positron emission tomography/CT, ceCT, and combined
cePET/CT correctly classified (true positive plus truenegative) 173, 153, and 179 patients, respectively. The
Cochran Q test evidenced a significant difference in the
comparison of the three techniques (Cochran Q = 26.08,
degrees of freedom (df ) = 2, P = 2 × 10-6). However, a
pairwise comparison using continuity-corrected McNe-
mar tests with Bonferroni adjustment revealed that cePET/
CT was not significantly different with respect to PET/
CT alone (McNemar chi-squared test = 1.5625, df = 1,
P = 0.21). Although not reaching significance, cePET/
CT presented better sensitivity, NPV, negative likelihood ra-
tio (NLR) and Youden’s index, when compared to PET/CT.
Patient-based performance comparisons between PET/CT
and combined cePET/CTare shown in Table 3.
Overall lesion-based analysis
A total of 597 lesions were detected. Among these, 431,
385, and 467 lesions were correctly evaluated (true posi-
tive plus true negative) by PET/CT, ceCT and combined
cePET/CT, respectively. The Cochran Q test evidenced a
significant difference between the three techniques (Cochran
Q= 58.3969, df = 2, P < 10-12). A pairwise comparison
using continuity-corrected McNemar tests with Bon-
ferroni adjustment revealed that the evaluation with
cePET/CT yielded significantly different results with
respect to PET/CT (McNemar chi-squared test = 30.96,
df = 1, adjusted P < 0.05). Performance comparisons be-
tween PET/CT and cePET/CT are shown in Table 4;
cePET/CT showed better sensitivity, NPV, NLR, and You-
den’s index compared to PET/CT. However, PET/CT
showed a slightly better specificity than cePET/CT.
Tumor-based lesion analysis
Table 5 lists the different types of tumor in which lesion-
based performance comparison was executed between
PET/CT and cePET/CT. The latter imaging modality
Table 4 Lesion-based analysis: performance comparisons
between PET/CT and cePET/CT
PET/CT cePET/CT
Sensitivity (%) 80.54 (76.41–84.10) 91.38 (88.25–93.74)
Specificity (%) 54.45 (47.37–61.36) 50.26 (43.24–57.28)
Positive predictive value (%) 78.99 (74.80–82.63) 79.61 (75.72–83.02)
Negative predictive value (%) 56.83 (49.59–63.79) 73.28 (65.12–80.12)
Positive likelihood ratio 1.77 (1.50–2.09) 1.84 (1.58–2.13)
Negative likelihood ratio 0.36 (0.28–0.45) 0.17 (0.12–0.24)
Diagnostic odds ratio 4.93 (3.39–7.21) 10.63 (6.85–16.84)
Error rate (%) 27.81 (24.36–31.53) 21.78 (18.65–25.26)
Accuracy (%) 72.19 (68.47–75.64) 78.22 (74.74–81.35)
Youden’s index 0.349 (0.352–0.347) 0.416 (0.418–0.414)
Estimated parameters corresponding to each technique are presented with a
95% confidence interval shown within parentheses. PET, positron emission
tomography; CT, computed tomography; cePET/CT, contrast-enhanced
PET/ CT.
Table 5 Statistical difference (P values) between the
performance of PET/CT and cePET/CT for each analyzed





















Response to chemotherapy 0.13
Response to radiotherapy 0.1
Post-surgery evaluation 0.54
Surveillance 0.51
aIncluding esophageal, gastric, and colorectal cancer.
bGynecologic malignancy n = 8 , testicular cancer n = 2, sarcoma n = 3,
low-differentiated neuroendocrine carcinoma n = 4, thymoma n = 1.
cSuspected relapse or patients with potentially resectable metastatic disease.
PET, positron emission tomography; CT, computed tomography; cePET/CT,
contrast-enhanced PET/ CT.
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standard PET/CT in head and neck cancer (McNemar
chi-squared test = 5.9, df = 1, P= 0.02) and gastrointestinal
cancer (McNemar chi-squared test = 13.1, df = 1, P = 0.0002)
patients. Table 6 lists the corresponding sensitivity and spe-
cificity values.
Site-based analysis of lesions
Five anatomical districts, including neck, thorax, abdo-
men, skeletal-bone marrow, and LNs (regardless of body
region), were evaluated in each patient. Contrast-enhanced
PET/CT results were significantly different with respect to
standard PET/CT in the abdominal region (McNemar chi-
squared test = 6.8, df = 1, P = 0.009). As expected, in the
subset of patients with abdominal lesions, the largest sub-
group was represented by patients with colorectal cancer
(n = 21) followed by non-Hodgkin lymphoma patients
(n = 12), while subgroups comprising patients affected
by other tumor types were smaller (five esophageal,
five breast, two ovarian, and four lung cancers, two
melanomas, one neuroendocrine tumor). Table 6 lists
the corresponding sensitivity and specificity values.
Question-based analysis of lesions
Table 1 lists the different clinical questions, submitted inde-
pendently from the lesion-based performance comparisonsTable 6 Performance of PET/CT and cePET/CT in tumors,
sites of disease, and clinical questions whose diagnostic




Head and neck cancer
Sensitivity (%) 71.33 (63.64–77.97) 82.67 (75.81–87.89)
Specificity (%) 46.30 (33.69–59.39) 48.15 (35.39–61.15)
Gastrointestinal cancera
Sensitivity (%) 71.25 (60.54–80.01) 95.00 (87.84–98.04)
Specificity (%) 84.21 (62.43–94.48) 89.47 (68.61–97.06)
Site of disease
Abdomen
Sensitivity (%) 97.53 (91.44–99.32) 92.59 (84.77–96.56)
Specificity (%) 46.15 (23.21–70.86) 92.31 (66.69–98.63)
Questions
Restagingb
Sensitivity (%) 83.96 (75.81–89.74) 96.23 (90.70–98.52)
Specificity (%) 78.37 (52.33–92.50) 78.57 (52.41–92.43)
Estimated parameters corresponding to each technique are presented with
95% confidence interval within parentheses.
aIncluding esophageal, gastric, and colorectal cancer.
bSuspected relapse or patients with potentially resectable metastatic disease.
PET, positron emission tomography; CT, computed tomography; cePET/CT,
contrast-enhanced PET/ CT.
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were significantly different with respect to standard PET/
CT when the scenario of disease restaging was considered
(McNemar chi-squared test = 8.5, df = 1, P = 0.003). Again,
among patients submitted for restaging, the largest sub-
group of patients was represented by patients with colorec-
tal cancer (n = 14) while all other patient subgroups were
smaller (three head and neck, three breast, four lung and
one ovarian cancers, five melanomas, three non-Hodgkin
lymphomas). Table 6 lists the corresponding sensitivity and
specificity values.
Impact on patient management
Findings that were detected only at the cePET/CT im-
aging modality resulted in a change of management for
15 of the 202 patients (7.4%). In particular, three patients
initiated a previously unplanned therapy, six patients
avoided inappropriate surgery, while a previously de-
cided medical treatment was spared in four patients. In
two patients, the use of cePET/CT significantly modified
the radiotherapy protocol. Adding ceCT produced more
distinct benefits, i.e. yielded a greater percentage of clin-
ical management modifications in selected tumor types
and clinical questions. In fact, the incremental value of
this diagnostic technique rose to 22% in patients with
head and neck cancer (5/23) and in 16% of patients with
gastrointestinal cancer (5/31). Finally, when patients
were grouped using the clinical question criterion, the
additional value of diagnostic ceCT was more evident in
the disease restaging setting (8/33 patients, 24.2%).
These patients, submitted to cePET/CT for restaging
purposes, were respectively affected by head and neck
cancer (n = 2), gastrointestinal cancer (n = 2), lung can-
cer (n = 1), non-Hodgkin lymphoma (n = 1), breast can-
cer (n = 1), and poorly differentiated neuroendocrine
carcinoma (n = 1).
The 15 patients whose management was changed by
cePET/CT, were classified according to the previouslyFigure 1 A 65-year-old male patient affected by pharyngeal cancer w
in the neck lymph nodes had been treated with surgery and radiothera
a small lymph node, which seems to infiltrate the upper esophagus. (b) As
node does not display increased FDG uptake. Subsequent endoesophageal u
patient was then submitted to chemotherapy. CT, computed tomography; PEexplained management-changing findings categorization,
as follows: category 1 = six patients; category 2 = three pa-
tients; category 3 = five patients; category 4 = one patient.
Representative cases are shown in Figures 1, 2, and 3.
Discussion
The present analysis does not support the routine use of
cePET/CT. In fact, our study confirms that, when clinic-
ally indicated, PET/CT executed with low-dose CT is
adequate for the workup of FDG-avid tumor types [2].
However, our analysis demonstrated that ceCT could im-
prove the diagnostic potential of hybrid imaging in spe-
cific clinical scenarios, where it can significantly impact
patient management.
In particular, patients affected by head and neck or
gastrointestinal cancer, and patients undergoing PET/CT
for evaluation of abdominal lesions and for restaging
purposes, seem to receive a greater benefit from imaging
protocols including both PET and ceCT. A greater diag-
nostic accuracy of cePET/CT has been indeed reported
in both head and neck and gastrointestinal cancer pa-
tients, with sensitivity and specificity comparable with
our results.
Head and neck cancer
Haerle et al. demonstrated that cePET/CT is superior to
PET/CT with regard to pathologically confirmed N0 ver-
sus N + status in head and neck cancer patients [19]. In
this study, sensitivity and specificity for correct N classi-
fication were respectively 70.7% and 50% for PET/CT
and 85.5% and 45.5% for cePET/CT. Similarly, Yoshida
et al. reported the superiority of cePET/CT over PET/
CT in the detection of head and neck malignancies [20].
Overall, these results are consistent with the fact that
the interpretation of FDG-PET/CT findings in the neck
can be challenging because of the numerous areas of
physiologic FDG uptake and also due to the frequently
observed pitfalls in post-treatment PET/CT imagingith lymph nodal relapse (secondary disease relapse: the first relapse
py one year before). (a) Axial, contrast-enhanced, full-dose CT shows
evident from contrast-enhanced PET/CT fused images, this lymph
ltrasound biopsy confirmed the presence of lymph node metastasis. The
T, positron emission tomography; FDG, [18 F] fluorodeoxyglucose.
Figure 2 A 54-year-old female patient previously submitted for surgical treatment for primary colon cancer and with a known, single
liver metastasis. This patient underwent contrast-enhanced PET/CT for the exclusion of other metastatic lesions, as she was a candidate for surgical
resection of the hepatic localization. (a) Axial, contrast-enhanced, full-dose CT shows a suspicious 8-mm solid lesion close to the small bowel. (b) The
lesion is highly FDG-avid on contrast-enhanced PET/CT. However, the pathologic nature of this finding is clearly evident only on contrast-enhanced CT,
whereas using standard CT, it could have been deemed as unspecific bowel FDG-activity. This patient thus avoided inappropriate surgical treatment
and was referred for chemotherapy. PET, positron emission tomography; CT, computed tomography; FDG, [18 F] fluorodeoxyglucose.
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tomy site or due to post-treatment edema of the mucosal
surfaces). Besides the complexity of neck anatomy, other
aspects related to each specific patient can also be advo-
cated. In fact, Haerle et al. highlighted a statistically sig-
nificant correlation between SUVmax and the degree of
necrosis in the involved neck LNs [19]. Actually, while the
presence of central necrosis in neck LNs is considered as
a reliable sign of LN metastasis at ceCT, these nodes are
often disregarded by non-enhanced PET/CT because of
the lack of FDG uptake in the necrotic, hypocellular tissue.
The presence of necrotic LNs can be predicted in some
cases, being more frequent in human papillomavirus-
associated head and neck squamous cell carcinoma [19].
Accordingly, in the present study, more than one-third of
patients whose management was changed by cePET/CT
had PET-negative or only faintly positive lesions, whose
presence could have been predicted before the exam. This
finding confirms that patients can be selected for cePET/
CT on the basis of their specific clinical history.Figure 3 A 51-year-old male patient, presenting tumor marker increase
CT showed a paravertebral lesion, which was slightly enlarged and significa
showed very mild FDG uptake; it was, however, classified as highly suspic
exam. Biopsy confirmed the presence of lung adenocarcinoma metastas
tomography; FDG, [18 F] fluorodeoxyglucose.Gastrointestinal cancer and abdominal imaging
Dirisamer et al. showed that the sensitivity and specifi-
city of PET/CT in colorectal cancer rose from 85 to
100% and from 70 to 81%, respectively, when contrast
medium was added to the CT component of the exam
[21]. More importantly, these authors showed that the
significant increase in sensitivity (which is similar to the
one highlighted in the present study) was due to a mis-
detection of 67% of the metastases at the standard PET/
CT exam. Interestingly enough, these metastases were
smaller than 8 mm in the majority of cases (94%). In-
deed, small metastatic lesions from colon cancer, located
within the liver or in the lung parenchyma, can show ab-
sent or only modest tracer uptake at PET/CT. Contrast
enhancement is particularly effective when evaluating le-
sions within the liver, as it allows the spotting and classifi-
cation of lesions as positive, small, and faintly FDG-avid,
otherwise missed by standard PET/CT. In this type of pa-
tient, other reasons for false-negative PET/CT results are
millimetric peritoneal metastatic spread or small peritonealafter surgery for lung cancer. (a) Axial, contrast-enhanced, full-dose
ntly more hyperemic with respect to a previous CT scan. (b) The lesion
ious on the basis of the contrast-enhanced CT component of the
is. Accordingly, the patient was referred for radiotherapy. CT, computed
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uptake, which are common in the intestinal tract [22]. In
the present study, the potential usefulness of cePET/CT in
the evaluation of patients with gastrointestinal cancer is
further testified by the fact that patients with colorectal
cancer represented the largest subgroup both in patients
with abdominal lesions and in patients submitted for re-
staging. In these two groups, we independently demon-
strated a significantly greater diagnostic accuracy of cePET/
CT with respect to standard PET/CT.Restaging in suspected cases or known disease relapse
Both these findings (tiny lesions or lesions close to sites
of physiologic FDG uptake), whenever undetected by
PET/CT, may significantly undermine the correct man-
agement of patients. Accordingly, these reasons account
for more than one-half of cePET/CT findings that demanded
a change of therapeutic strategy in patients included in the
present study and are indeed especially relevant as they can
avoid inappropriate surgery. On the other hand, ceCT alone
showed limited capability in differentiating disease recur-
rence from post-radiotherapy tissue reaction, while PET/CT
displayed a good performance in telling apart these two set-
tings, owing to its intrinsic capacity to identify viable
tumor tissue [23]. Overall, both very small lesions, which
are likely to produce false-negatives at PET/CT, and local,
post-therapy changes, which are likely to prove a diagnos-
tic challenge at ceCT alone, are particularly relevant in pa-
tients submitted to medical imaging for restaging or for
the preoperative workup of metastatic lesions, candidates
for surgical resection. Altogether, these findings strongly
suggest that restaging of patients with gastrointestinal
cancer could be one of the main indications for cePET/
CT use.Patient selection based on criteria other than tumor type
Despite the advantages of cePET/CT highlighted here
and in previous studies, the use of cePET/CT is still not
justified for clinical routine examinations due to higher
costs, increased radiation burden, and potential adverse
drug reaction to the intravenous contrast medium. More-
over, to obtain an accurate fusion of the two image sets,
ceCT should be performed without repositioning the
patient. This demands the presence of a physician for
immediate image assessment after the standard PET/
CT examination, thus resulting in a lowered patient
throughput, because of additional time requirements
for image review [24]. Therefore, given the demands
for FDG-PET/CT and the number of available PET/CT
scanners, the diffusion of cePET/CT as a ‘one-stop-
shop’ examination for all patients submitted to PET/
CT does not presently appear to be the most appropri-
ate choice.In this scenario, our approach pinpoints the situations
where cePET/CT could be of benefit, not only on the
basis of tumor type, but also according to the criteria re-
lated to the site of lesions and to the clinical question.
This multiple parameter statistical analysis further de-
fines the subsets of patients that can be candidates for
cePET/CT, on the basis of their specific clinical history.
The present study suggests that these patients have to
be specifically identified, for example, in the context of
oncologic, multidisciplinary, disease-management team
discussions.
Limitations
The present study has several limitations. It was a
single-center, retrospective study whose results may have
been influenced by its study population, including cancer
patients with both initial and recurrent disease. More-
over, due to ethical reasons, the histologic verification of
metastasis was not performed for all distant lesions.
However, as in other studies, the presence of metastasis
was verified with a 1-year imaging follow-up, to ensure
the highest possible confidence. We should also under-
line that we did not directly compare the diagnostic per-
formance of PET/CT with separate CT as we focused on
the specific added value of ceCT with respect to stand-
ard PET/CT. Finally, as many workstations and several
freeware software programs allow to fuse PET and ceCT
images, and as ceCT is becoming more and more a
‘frontline’ investigation, a further question concerns the
different diagnostic accuracy of combined cePET/CT ob-
tained in a single session with respect to the off-line
image fusion of PET images with a recently obtained CT
scan. This issue, which is crucial and the object of active
work and discussion within radiological and nuclear
medicine societies, is presently beyond the aims of our
study and deserves further specific investigation.
Conclusion
We have highlighted a significant benefit of adding ceCT
to PET/CT hybrid imaging in patients with head and
neck or gastrointestinal cancer. This imaging modality
was particularly helpful in the setting of disease re-
staging, in the presence of increased tumor markers, or
in the case of metastatic lesions candidate for surgical
treatment. Similarly, regardless of tumor type, lesions lo-
cated within the abdomen were also more correctly clas-
sified thanks to the help of diagnostic ceCT. The present
study could not highlight such a significant benefit in
the general population of oncology patients submitted to
standard FDG-PET/CT, which should be preferred when
clinically indicated. Accordingly, these data strongly
underline the importance of strictly selecting patients
for the combined exam. In the age of personalized medi-
cine and multidisciplinary approaches in oncology patients,
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http://www.cancerimagingjournal.com/content/14/1/10the present results allow us to propose a clinical, history-
related criterion when selecting candidates for cePET/CT,
thus allowing the right imaging workup for the right pa-
tient without lowering patient throughput and without
causing an unjustified increase in radiation burden.
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